UY32721A - Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados - Google Patents

Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados

Info

Publication number
UY32721A
UY32721A UY0001032721A UY32721A UY32721A UY 32721 A UY32721 A UY 32721A UY 0001032721 A UY0001032721 A UY 0001032721A UY 32721 A UY32721 A UY 32721A UY 32721 A UY32721 A UY 32721A
Authority
UY
Uruguay
Prior art keywords
hcv
viruses
pharmaceutical compositions
related methods
useful pharmaceutical
Prior art date
Application number
UY0001032721A
Other languages
English (en)
Inventor
William E Delaney
Mo Hongmei
Zhong Weidong
Original Assignee
Gilead Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Ltd filed Critical Gilead Sciences Ltd
Publication of UY32721A publication Critical patent/UY32721A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

Esta invención está relacionada con combinaciones del Compuesto 1 y del Compuesto 2 que son útiles para tratar una infección causada por el virus de la hepatitis C.
UY0001032721A 2009-06-23 2010-06-18 Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados UY32721A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21964609P 2009-06-23 2009-06-23

Publications (1)

Publication Number Publication Date
UY32721A true UY32721A (es) 2011-01-31

Family

ID=42536374

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032721A UY32721A (es) 2009-06-23 2010-06-18 Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados

Country Status (5)

Country Link
US (1) US20100324059A1 (es)
AR (1) AR077138A1 (es)
TW (1) TW201113279A (es)
UY (1) UY32721A (es)
WO (1) WO2010151487A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2483273A4 (en) * 2009-09-28 2013-05-01 Hoffmann La Roche NOVEL MACROCYCLIC INHIBITORS FOR HEPATITIS C VIRUS REPLICATION
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
DE202012012954U1 (de) 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20070015553A1 (en) 2005-07-12 2007-01-18 Microsoft Corporation Compact and durable clamshell smartphone
SI2038275T1 (sl) 2006-07-07 2010-06-30 Gilead Sciences Inc Nova piridazinska spojina in njena uporaba
DK2038290T3 (da) * 2006-07-07 2013-12-02 Gilead Sciences Inc Modulatorer af toll-lignende receptor 7
CN101784548B (zh) * 2007-06-29 2013-07-17 吉里德科学公司 嘌呤衍生物及其作为toll样受体7的调节剂的用途

Also Published As

Publication number Publication date
WO2010151487A1 (en) 2010-12-29
TW201113279A (en) 2011-04-16
US20100324059A1 (en) 2010-12-23
AR077138A1 (es) 2011-08-03

Similar Documents

Publication Publication Date Title
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
GT201300093A (es) Compuestos antivirales
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
ECSP14013315A (es) Inhibidores de aplicación viral
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
CO6440581A2 (es) Inhibidores del virus de la hepatitis c
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201270622A1 (ru) Ингибиторы вируса гепатита с
EA201391152A1 (ru) Ингибиторы вируса гепатита с
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
UY32457A (es) Vacuna del virus del dengue inactivado
UY34066A (es) Inhibidores del virus de la hepatitis c
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
CL2016000300A1 (es) Métodos terapéuticos
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
CO6290645A2 (es) Compuesto para el tratamiento de la hepatitis c
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
CY1117188T1 (el) Αντι-ιικο παραγωγο 1-φαινυλ-2,5-διβενζιμιδαζολ-5-υλ-πυρρολιδινης

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190219